Next Article in Journal
An Exploratory Study of Student Pharmacists’ Self-Reported Pain, Management Strategies, Outcomes, and Implications for Pharmacy Education
Previous Article in Journal
Pharmacy Practice and Education in Latvia
Article

Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs

1
Drug Department of Local Health Unit (ASP), Viale Giostra, 98168 Messina, Italy
2
Clinical Pharmacy Fellowship, University of Messina, Viale Annunziata, 98168 Messina, Italy
*
Author to whom correspondence should be addressed.
Pharmacy 2018, 6(1), 10; https://doi.org/10.3390/pharmacy6010010
Received: 12 November 2017 / Revised: 8 January 2018 / Accepted: 11 January 2018 / Published: 21 January 2018
Prevention and treatment of dyslipidemia should be considered as an integral part of individual cardiovascular prevention interventions, which should be addressed primarily to those at higher risk who benefit most. To date, statins remain the first-choice therapy, as they have been shown to reduce the risk of major vascular events by lowering low-density lipoprotein cholesterol (LDL-C). However, due to adherence to statin therapy or statin resistance, many patients do not reach LDL-C target levels. Ezetimibe, fibrates, and nicotinic acid represent the second-choice drugs to be used in combination with statins if lipid targets cannot be reached. In addition, anti-PCSK9 drugs (evolocumab and alirocumab) provide an effective solution for patients with familial hypercholesterolemia (FH) and statin intolerance at very high cardiovascular risk. Recently, studies demonstrated the effects of two novel lipid-lowering agents (lomitapide and mipomersen) for the management of homozygous FH by decreasing LDL-C values and reducing cardiovascular events. However, the costs for these new therapies made the cost–effectiveness debate more complicated. View Full-Text
Keywords: lipid lowering therapy; dyslipidemia; statins; fibrate; PCSK9 inhibitors; lomitapide lipid lowering therapy; dyslipidemia; statins; fibrate; PCSK9 inhibitors; lomitapide
Show Figures

Figure 1

MDPI and ACS Style

Zodda, D.; Giammona, R.; Schifilliti, S. Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs. Pharmacy 2018, 6, 10. https://doi.org/10.3390/pharmacy6010010

AMA Style

Zodda D, Giammona R, Schifilliti S. Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs. Pharmacy. 2018; 6(1):10. https://doi.org/10.3390/pharmacy6010010

Chicago/Turabian Style

Zodda, Donatella, Rosario Giammona, and Silvia Schifilliti. 2018. "Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs" Pharmacy 6, no. 1: 10. https://doi.org/10.3390/pharmacy6010010

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop